model updat thought speak
compani second opinion
pharma continu drive stori strong show today
lead pharma sector ahead overal market
rais tighten ep guidanc investor appear
shrug lower sale guidanc essenti
remov ad currenc benefit incorpor
guidanc last quarter lower oper growth outlook vs
led wonder drive continu recoveri
share continu look pharma busi drive stori
especi key product stelara xarelto newer asset
tremfya erleada import upcom catalyst includ data
command marin trial xarelto result
head-to-head trial tremfya vs cosentyx psoriasi move
heart earn season next week increment
optimist pharma group clariti around drug price would
certainli help increas interest group believ may come
move us mid-term elect and/or approach dec
deadlin essenti place trump administr
implement propos administr blueprint drug
valuat maintain outperform rate lower target price
rel valuat blue sky valuat
grey sky valuat ep estim increas
ep remain pleas
let us know would like updat compani model
risk primari risk rate target price slowdown
key pharma growth driver disappoint data on-going
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
price jul rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
opportun speak member ir team follow
confer call gain addit clariti dynam around certain product
well bake expect around fy
summar compani answer question
report diabet
contribut approxim growth oper basi longer
account
report specialti surgeri
compani yet made decis accept offer
accept deal would close
guidanc given deal impact would prematur
asp slight declin recent saw mid-single-digit growth
report within orthoped
report hip
potenti knee also would report well
us-onli product look expand ww
term deal disclos
one-tim impact babi impact
get back growth rate ex-a
overal market under-penetrated
plenti room competit entri
hold lion share market
market sever year
expect gener sustenna launch year
phase excit
hard say market penetr could point
target patient popul expos biolog
biologic-nav
track biolog patient prior tremfya
could tnf etc
prospect gener entri come trial
run week
time-fram offer rule
feel strongli patent strength expect competit
event would end month stay octob
judg yet rule gener approv could
launch risk
releas sale data yet still rel new small
track expect
indic non-metastat zytiga indic metastat
impact gener zytiga indic
total market size twice zytiga
pleas uptravi opsumit quarter
lessen impact patient assist foundat
expect ratio stabil point move forward
strongli believ deal valu creat
believ combin therapi provid signific growth potenti
us million unless otherwis state
sale
sale
sale
sale
figur cs comparison guidanc
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
good sold
total expens incom
incom tax basi
ep continu op
dilut ep oper
us million unless otherwis state
prepaid expens
loan note payabl
accru rebat return promot
note receiv employe stock ow nership
accumul incom
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
compani mention price
